达格列净在射血分数轻度降低或保留的心力衰竭患者中按基线血糖状态分层的疗效与安全性(DELIVER):一项国际多中心双盲随机安慰剂对照试验的亚组分析
DELIVER试验的亚组分析纳入6263例射血分数轻度降低或保留的心力衰竭患者,按基线血糖状态分为血糖正常、糖尿病前期和2型糖尿病三组。达格列净在三个亚组中均降低主要终点风险,且各亚组间无显著交互作用;容量相关或肾脏严重不良事件、低血糖及截肢在各血糖类别中未受治疗差异影响。
要点
- 达格列净在血糖正常、糖尿病前期和2型糖尿病三个亚组中均降低主要终点风险。
- 主要终点发生率随血糖状态恶化而升高,血糖正常组6.9/100患者年,2型糖尿病组10.1/100患者年。
- 容量相关或肾脏严重不良事件、低血糖及截肢在各血糖类别中未受治疗差异影响。
核心结论
- 在射血分数轻度降低或保留的心力衰竭患者中,口服达格列净在血糖正常、糖尿病前期和2型糖尿病三个亚组中相似程度地改善心力衰竭结局。
- 达格列净的心力衰竭获益似乎在连续血糖范围内保持一致。
研究设计与样本
- DELIVER为国际、多中心、双盲、随机、安慰剂对照试验,在20个国家的350个医疗中心和医院进行。
- 纳入年龄40岁及以上、NYHA心功能II-IV级、左心室射血分数大于40%、利钠肽升高(窦性心律者N末端B型利钠肽原≥300 pg/mL,心房颤动或扑动者≥600 pg/mL)且有结构性心脏病证据的患者。
- 患者按1:1随机分配至口服达格列净10 mg或安慰剂,中位随访2.3年(IQR 1.7-2.8)。
- 全分析集包括所有随机分配至研究治疗的患者,按随机治疗分配分析(意向治疗);安全性分析集包括随机分配至研究治疗且至少服用一剂研究产品的患者,按实际接受治疗分析。
- 2018年9月1日至2021年1月18日共随机分配6263例患者至达格列净(n=3131)或安慰剂(n=3132);其中1175例血糖正常、1934例糖尿病前期、3150例2型糖尿病纳入血糖亚组分析;3515例(56.2%)为男性,4435例(70.9%)为白人。
主要发现
- 主要终点发生率在血糖正常亚组为6.9/100患者年(参照),糖尿病前期亚组为7.6/100患者年(HR 1.09 [95% CI 0.90-1.31]),2型糖尿病亚组为10.1/100患者年(HR 1.46 [95% CI 1.24-1.73];趋势p<0.0001)。
- 达格列净 versus 安慰剂降低主要终点风险:血糖正常亚组HR 0.77(95% CI 0.57-1.04),log-rank p=0.088;糖尿病前期亚组HR 0.87(95% CI 0.69-1.08),log-rank p=0.21;2型糖尿病亚组HR 0.81(95% CI 0.69-0.95),log-rank p=0.0077;交互作用p=0.82。
- 在连续HbA1c范围内,达格列净 versus 安慰剂的疗效一致(交互作用p=0.85)。
- 容量相关或肾脏严重不良事件、导致研究药物停用的不良事件、低血糖及截肢在任何血糖类别中均未受治疗差异影响。
关键数值与推荐
- 2型糖尿病定义为基线有糖尿病史或HbA1c≥6.5%(48 mmol/mol);糖尿病前期定义为基线HbA1c 5.7至<6.5%(39 mmol/mol至<48 mmol/mol);血糖正常定义为基线HbA1c<5.7%(39 mmol/mol)。
- 主要终点为随机化至首次心力衰竭恶化事件(定义为需要静脉治疗的非计划住院或紧急心力衰竭就诊)或心血管死亡的复合终点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Type 2 diabetes and prediabetes are risk factors for heart failure and adverse heart failure outcomes. The Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial showed that dapagliflozin was associated with a reduction in the primary outcome of worsening heart failure or cardiovascular mortality in patients with heart failure with mildly reduced or preserved ejection fraction. We aimed to assess the efficacy and safety of oral dapagliflozin in these patients by their baseline glycaemia categories. METHODS: DELIVER was an international, multicentre, double-blind, randomised, placebo-controlled trial done in 350 health-care centres and hospitals across 20 countries. Patients aged 40 years or older with New York Heart Association class II-IV, left ventricular ejection fraction of more than 40%, elevated natriuretic peptides (N-terminal pro B-type natriuretic peptide ≥300 pg/mL or ≥600 pg/mL for patients in atrial fibrillation or flutter), and evidence of structural heart disease were randomly assigned (1:1) to 10 mg dapagliflozin or placebo, administered orally, and followed up for a median of 2·3 years (IQR 1·7-2·8). The primary outcome, a composite of time from randomisation to first worsening heart failure events (defined as an unplanned hospitalisation or urgent heart failure visit requiring intravenous therapy) or cardiovascular death, in participants with type 2 diabetes (history of or identified by HbA1c ≥6·5% [48 mmol/mol] at baseline) or prediabetes (HbA1c 5·7 to <6·5% [39 mmol/mol to <48 mmol/mol] at baseline) was compared with those with normoglycaemia (HbA1c <5·7% [39 mmol/mol]). Efficacy of dapagliflozin versus placebo was assessed according to glycaemic status and based on HbA1c as a continuous measure. The full-analysis set comprised all patients who were randomly assigned to study treatment, with patients analysed according to their randomised treatment assignment, irrespective of the treatment received (ie, intention to treat). The safety analysis set comprised patients who were randomly assigned to study treatment and who took at least one dose of investigational product, with patients analysed according to the treatment actually received. This trial is registered with ClinicalTrials.gov, NCT03619213. FINDINGS: Between Sept 1, 2018, and Jan 18, 2021, 6263 patients were randomly assigned to oral dapagliflozin (n=3131) or placebo (n=3132). Of these patients, 1175 had normoglycaemia, 1934 had prediabetes, and 3150 had type 2 diabetes and were included in the glycaemia subgroup analysis (3515 [56·2%] of 6263 patients were men and 4435 [70·9%] were White). The incidence rate of the primary outcome was 6·9 per 100 patient-years in the normoglycaemia subgroup (reference), increasing to 7·6 per 100 patient-years in the prediabetes subgroup (hazard ratio 1·09 [95% CI 0·90-1·31]) and 10·1 per 100 patient-years in the type 2 diabetes subgroup (1·46 [1·24-1·73]; p<0·0001 for trend). Dapagliflozin reduced the risk of the primary outcome versus placebo in each subgroup (hazard ratio 0·77 [95% CI 0·57-1·04], log-rank p=0·088, for patients with normoglycaemia, 0·87 [0·69-1·08], log-rank p=0·21, for patients with prediabetes, and 0·81 [0·69-0·95], log-rank p=0·0077, for patients with type 2 diabetes; pinteraction=0·82) and across the continuous HbA1c range (pinteraction=0·85). Volume-related or renal serious adverse events or adverse events leading to discontinuation of the study drug, hypoglycaemia, and amputations were not differentially affected by treatment in any of the glycaemia categories. INTERPRETATION: In patients with heart failure with mildly reduced or preserved ejection fraction, oral dapagliflozin improved heart failure outcomes to a similar extent in three glycaemia subgroups: normoglycaemia, prediabetes, and type 2 diabetes. Moreover, the heart failure benefits of dapagliflozin seem to be consistent across a continuous glycaemic range. FUNDING: AstraZeneca.
引用
- Inzucchi SE, Claggett BL, Vaduganathan M, et al. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2022. PMID: 36372069. doi:10.1016/S2213-8587(22)00308-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。